Shares of Organogenesis Holdings ORGO increased in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share rose 143.75% year over year to $0.07, which beat the estimate of ($0.02).
Revenue of $102,552,000 higher by 66.12% from the same period last year, which beat the estimate of $87,570,000.
Looking Ahead
Organogenesis Sees FY21 Sales Guidance Of $438M-$454M Vs $397.24M Estimates
How To Listen To The Conference Call
Date: May 10, 2021
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/h25z7drp
Recent Stock Performance
Company's 52-week high was at $24.34
52-week low: $3.01
Price action over last quarter: Up 12.72%
Company Overview
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
